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Abstract
Background: Identification of the determinants of access to investigational drugs is important to promote equity
and scientific validity in clinical research. We aimed to analyze factors associated with the use of experimental
antiretrovirals in Italy.
Methods: We studied participants in the Italian Cohort of Antiretroviral-Naive Patients (ICoNA). All patients 18 years
or older who had started cART (≥ 3 drugs including at least two NRTI) after their enrolment and during 1997-2007
were included in this analysis. We performed a random effect logistic regression analysis to take into account
clustering observations within clinical units. The outcome variable was the use of an experimental antiretroviral,
defined as an antiretroviral started before commercial availability, in any episode of therapy initiation/change. Use
of an experimental antiretroviral obtained through a clinical trial or an expanded access program (EAP) was also
analyzed separately.
Results: A total of 9,441 episodes of therapy initiation/change were analyzed in 3,752 patients. 392 episodes (360
patients) involved an experimental antiretroviral. In multivariable analysis, factors associated with the overall use of
experimental antiretrovirals were: number of experienced drugs (≥ 8 drugs versus “naive": adjusted odds ratio
[AOR] = 3.71) or failed antiretrovirals(3-4 drugs and ≥ 5 drugs versus 0-2 drugs: AOR = 1.42 and 2.38 respectively);
calendar year (AOR = 0.80 per year) and plasma HIV-RNA copies/ml at therapy change (≥ 4 log versus < 2 log: AOR
= 1.55). The probability of taking an experimental antiretroviral through a trial was significantly lower for patients
suffering from liver co-morbidity(AOR = 0.65) and for those who experienced 3-4 drugs (vs naive) (AOR = 0.55),
while it increased for multi-treated patients(AOR = 2.60). The probability to start an experimental antiretroviral
trough an EAP progressively increased with the increasing number of experienced and of failed drugs and also
increased for patients with liver co-morbidity (AOR = 1.44; p = 0.053). and for male homosexuals (vs heterosexuals:
AOR = 1.67). Variability of the random effect associated to clinical units was statistically significant (p < 0.001)
although no association was found with specific characteristics of clinical unit examined.
Conclusions: Among patients with HIV infection in Italy, access to experimental antiretrovirals seems to be
influenced mainly by exhaustion of treatment options and not by socio-demographic factors.
Keywords: antiretroviral therapy, experimental drug, HIV, cohort study, clinical trial, expanded access program, mul-
tilevel analysis
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Removing the barriers to accessing experimental drugs
is an important goal from both a scientific and ethical
point of view. In fact, generalizable therapeutic research
requires a study population that is representative of the
population that will eventually be in need of the drug
being studied [1,2]. Moreover, for patients with serious
or life-threatening diseases who cannot be treated effec-
tively with approved drugs, access to experimental drugs
may represent the only possible way of receiving effec-
tive treatment [3].
The issue of accessing experimental drugs has been
debated for persons with HIV infection since the first dec-
ade of the epidemic. When the first antiretrovirals entered
clinical trials, in response to the need of patients for
whom no effective treatment was available, the US issued
a new regulation that allowed experimental drugs to be
distributed outside clinical trials in the context of so-called
Expanded access programs (EAP) [4]. Subsequently, simi-
lar regulations were issued in other countries [5].
Since zidovudine was first approved for clinical use,
the possibility of treating HIV infection has dramatically
expanded and more than 20 drugs are now available in
industrialized countries [6]. Nonetheless, there is still a
sizeable population of patients who experience virologi-
cal failure to the three main classes of antiretrovirals
and need access to new drugs [7,8].
Knowledge of patterns of access to experimental drugs
by persons with HIV is still incomplete. A number of
studies have analyzed the barriers that prevent access to
clinical trials of antiretroviral drugs. Cross-sectional sur-
veys on HIV patients conducted in North America
found that ethnic minorities, women and patients with
public or no health care insurance were underrepre-
sented in clinical trials [9-14]. In European studies, the
mode of HIV transmission and socio- economic status
were reported to be associated with participation in clin-
ical trials [15,16]. On the other hand, little information
is available on the overall access to experimental drugs
(through clinical trials or EAPs). A survey conducted on
a probability sample of US patients with HIV found that
ethnic minorities and persons cared for in private health
maintenance organizations had a lower probability of
receiving experimental drugs [17].
The aim of our study was to analyze the access to
experimental antiretrovirals and the variation over time
in the context of a national health service providing uni-
versal access to antiretroviral treatment. To this end we
analyzed data recorded between 1997 and 2007 in a
multicentre cohort study in Italy conducted on patients
with HIV infection who were antiretroviral naïve at the
time of enrolment [18].
Methods
This analysis was conducted within the Italian Cohort of
Antiretroviral-Naive Patients (ICoNA) study, an obser-
vational cohort of HIV-infected individuals who were
antiretroviral naïve at enrolment [18]. This cohort was
set up in January, 1997 and to date consists of more
than 7,000 patients from 50 infectious disease units in
Italy. Initiation and discontinuation dates of each antire-
troviral drug, HIV-viral load and CD4 cell count at each
clinical visit (every 4-6 months on an average) were
recorded for each enrolled patient.
Ethics statement
All individuals signed an informed consent prior to
enrolment and the study was approved by the Ethics
Committee of each participating institution that are
listed in an appendix.
All patients 18 years or older who had started cART
(≥ 3 drugs including at least two NRTI) during 1997-
2007 were included in this analysis.
For each subject included in the analysis we analyzed
the “episodes of therapy initiation/change”, defined as
any initiation of a single antiretroviral drug as part of
the initial or subsequent regimen.
The initiation of a co-formulated drug without change
in the component medicaments of the regimen was con-
sidered as a therapy change. On the other hand, change
of therapeutic regimen, consisting of discontinuation of
a drug without substitution, is not included in this defi-
nition and we did not consider consecutive prescriptions
o ft h es a m ea n t i r e t r o v i r a ls e p arated by discontinuation.
A CD4 count and a viral load determination had to be
available within 6 months before and 15 days after ther-
apy initiation/change for the episode to be included in
the analysis.
We speculated that for physician and patient, there is
a chance of starting an experimental antiretroviral when
a new regimen is started or a new drug is introduced in
a cART combination. For the purpose of this analysis,
we defined an experimental antiretroviral as any antire-
t r o v i r a ld r u gs t a r t e dw h e ni tw a sn o ty e tl i c e n s e dt ob e
legally marketed and sold in Italy (Table 1). If participa-
tion in a clinical trial was not recorded and the experi-
mental antiretroviral was started after the first ethical
approval of an EAP for that drug in Italy, we assumed
that the drug was obtained through an EAP; otherwise
the experimental antiretroviral was considered to be
obtained through a clinical trial.
Statistical analysis
Descriptive statistical techniques were used to provide a
general profile of the study population.
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Page 2 of 12The temporal trend in the use of experimental antire-
troviral was evaluated by plotting the proportion of ther-
apy initiation/change by calendar year.
We computed the proportion of therapy initiation/
change with an experimental antiretroviral through a
trial and an EAP by the clinical centre and we evaluated
the association between them by using Pearson’sc o r r e -
lation coefficient.
Univariable association between the distribution of
episodes of therapy initiation/change according to the
presence of an experimental antiretroviral and selected
characteristics were tested using a Pearson’sc h i - s q u a r e
test stratified by clinical centre [19].
Outcome variables
Multivariable logistic models were performed to assess
adjusted odds ratios (AOR) for initiation of an experi-
mental antiretroviral. In model 1 the outcome variable
was the overall use of experimental antiretroviral drugs,
regardless of whether the drug was obtained through a
clinical trial or an EAP. In model 2 the outcome variable
was the use of an experimental antiretroviral obtained
through a trial, and in model 3 the outcome variable
was the use of an experimental antiretroviral obtained
through an EAP.
Correlation between statistical units coming from the
same clinical centre was taken into account by adding
a random intercept to the models. We did not take
into account clustering observations within patients
since this outcome was a rare event (4%), and clusters
without events would have been dropped by the analy-
sis [20].
The covariates introduced in the models concerned
the characteristics of clinical centres (categorized as hos-
pital vs. university/research centre and number of
reported AIDS cases), demographic, epidemiological
(gender, age at therapy change, country of origin, occu-
pation, marital status, years of education, HIV exposure
category) and clinical characteristics of the subjects
(clinical stage of HIV disease, CD4 cell count, plasma
HIV-RNA, presence of cardio-vascular/metabolic dis-
eases or neoplasm, presence of liver comorbitidy (liver
diseases and/or HBsAg positivity and/or anti-HCV posi-
tivity) at the time of therapy change.
We also analyzed variables indicating exhaustion of
treatment options, by considering the number of experi-
enced antiretroviral drugs and of virologically failed
antiretroviral drugs (defined as plasma HIV-RNA above
500 copies per mL after more than 4 months of contin-
uous use of the drug) [21]. In order to take into account
the different availability over time of experimental anti-
retrovirals, we also adjusted the estimates for the calen-
dar year of antiretroviral prescription.
Analyses were performed with Stata Statistical Soft-
ware: Release 10 (Stata Corp, College Station, Tex).
Table 1 Year of regulatory approval in Italy of antiretroviral drugs, 1987-2008
Year NRTI NNRTI PI EI II
1987 Zidovudine (AZT)
1992 Didanosine
1995 Zalcitabine
1996 Stavudine
Lamivudine (3TC)
Indinavir
Ritonavir
Saquinavir HG
1998 AZT/3TC Co-formulation Nevirapine Nelfinavir
1999 Abacavir (ABC) Efavirenz Saquinavir SG
2001 ABC/AZT/3TC Co-formulation Amprenavir
Lopinavir/Ritonavir
2002 Tenofovir (TDF)
2004 Atazanavir Enfuvirtide
2005 Emtricitabine (FTC)
TDF/FTC Co-formulation
ABC/3TC Co-formulation
Fosamprenavir
Tripanavir
2007 Darunavir
a
2008 Maraviroc
a Raltegravir
a
Not approved Delavirdine
Atevirdine
DP 083
NRTI = Nucleoside Reverse Transcriptase Inhibitor; NNRTI = Non-nucleoside Reverse Transcriptase Inhibitor; PI = protease inhibitors; EI = Entry
and Fusion Inhibitors; II = Integrase Inhibitor
a Not used in the IcoNa cohort prior to regulatory approval
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Patients
3,752 patients were included in our analysis (Figure 1).
The median age at enrolment was 37 years (inter-quar-
tile range [IQR]: 32.7-42.5). Women accounted for
2 9 . 6 %o ft h et o t a ls t u d yp o p u l a t i o n .T h em a j o r i t yo f
patients were born in Italy (92.4%). With regard to HIV
exposure category, individuals infected through hetero-
sexual contacts accounted for 38.5%, through homosex-
ual contacts for 21.4%, and those infected through
injecting drug use for 33.6% of the total.
The median CD4 cell count at baseline was 279/mm
3
(IQR: 139-429.5); HIV-viral load at baseline (log 10
copies/ml) was 4.73 (IQR: 4.07-5.23). Clinically defined
AIDS was present at enrolment in 16.9% of patients,
while liver comorbitidy was present in 40.8%. 45.6% of
patients were cared for in a teaching hospitals.
Episodes of therapy initiation/change
A total of 9,441 episodes of therapy initiation/change
were analyzed of which 392 episodes, related to 360
patients (9.6% of total), involved an experimental antire-
troviral. In 192 episodes (in 188 patients, 5.0% of the
total) the experimental drug was obtained through a
trial, and in 200 (in 172 patients, 4.6% of the total)
through an EAP.
The trend in experimental antiretroviral use during
the study period is shown in Figure 2; this trend partly
reflects the availability of clinical trials or EAPs over
time in Italy (data not shown). The proportion of epi-
sodes of therapy initiation/change involving the use of
an experimental antiretroviral obtained through a trial
varied markedly in different years and peaked in 1998 at
7.7%. A marked variability was also observed for a pro-
portion of episodes of therapy initiation/change invol-
ving the use of an experimental antiretroviral obtained
through an EAP which peaked (7.2%) in 1999.
The proportion of therapy initiation/change with an
experimental antiretroviral (Figure 3), ranges between
0.0 and 10.3% for trials and 0.0 and 6.2% for EAPs in
different clinical centres. There was a significant correla-
tion (r = 0.27, p = 0.04) between the proportion of regi-
men changes/initiation with an experimental
antiretroviral obtained through a trial and through an
EAP by clinical centre.
Table 2 shows distribution of episodes of therapy
initiation/change according to the presence of an experi-
mental antiretroviral, by socio-demographic, behavioural
Figure 1 Flow diagram of patients included in this analysis.
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Page 4 of 12and clinical characteristics of the patients and character-
istics of the clinical centre. In univariable analysis, the
characteristics of the clinical centre where the patient
was cared for, viral load, presence of liver comorbidities
and previous antiretroviral treatment at the time of
therapy change were associated with probability of
receiving an experimental antiretroviral.
In multivariable logistic regression (Table 3), the prob-
ability of receiving an experimental antiretroviral
through a trial or an EAP (model 1) decreased
Figure 2 Proportion of regimen initiation/changes involving an experimental antiretroviral by calendar year.
Figure 3 Regimen changes involving an experimental antiretroviral through clinical trials or expanded access programs (EAP) in each
clinical centre.
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Page 5 of 12Table 2 Use of experimental antiretroviral drugs in a therapy initiation/change episode by demographic/
epidemiological characteristics of patients and clinical and laboratory data at the time antiretroviral treatment (ART)
initiation/change
Therapy initiation/change
episodes including an
experimental antiretroviral
Total therapy initiation/change episodes p-value
In clinical trial
N (%)
In EAP
a
N (%)
Total reported AIDS cases in the clinical centre 0.02
0-250 34 (2.2) 34 (2.2) 1.575
251-500 54 (2.7) 46 (2.3) 2.004
501-1000 54 (2.4) 42 (1.9) 2.212
> 1000 50 (1.4) 78 (2.1) 3.650
Type of clinical centre 0.05
Non-teaching hospital 113 (2.3) 118 (2.4) 4.993
Teaching hospital 79 (1.8) 82 (1.8) 4.448
Gender 0.80
Females 56 (1.9) 58 (2.0) 2.889
Males 136 (2.1) 142 (2.2) 6.552
Age at ART initiation/change 0.48
18-34 67 (2.5) 56 (2.1) 2.687
35-39 48 (1.8) 60 (2.3) 2.609
40-44 40 (2.0) 37 (1.9) 1.960
> = 45 37 (1.7) 47 (2.2) 2.185
Place of birth 0.36
Italy 178 (2.0) 191 (2.2) 8.774
Other countries 14 (2.1) 9 (1.3) 667
Years of education 0.22
< = 8 78 (1.7) 90 (1.9) 4.624
9-13 55 (2.2) 56 (2.2) 2.530
> 13 10 (2.3) 11 (2.5) 432
Unknown 49 (2.6) 43 (2.3) 1.855
Marital status 0.29
Never married 93 (1.9) 94 (1.9) 4.864
Married 99 (2.2) 106 (2.3) 4.577
Occupational status 0.53
Unemployed 47 (2.0) 47 (2.0) 2.345
Employed 138 (2.1) 145 (2.2) 6.675
Other 7 (1.7) 8 (1.9) 421
HIV exposure category 0.08
Heterosexual 73 (2.0) 68 (1.9) 3.597
Homosexual/Bisexual 48 (2.4) 58 (2.9) 2.010
IDU (Active+Former) 56 (1.7) 65 (2.0) 3.237
Other/Unknown 15 (2.5) 9 (1.5) 597
Nadir CD4 cell count (cells/ml) 0.07
< 200 86 (2.0) 104 (2.4) 4348
200-349 51 (1.7) 51 (1.7) 2965
> = 350 55 (2.6) 45 (2.1) 2128
Clinical and laboratory data at treatment initiation/change
Clinical AIDS 0.10
No 161 (2.1) 151 (2.0) 7.600
Yes 31 (1.7) 49 (2.7) 1.841
CD4 cell count (cells/ml) 0.10
< 200 64 (2.7) 56 (2.3) 2387
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Page 6 of 12significantly over time (adjusted odds ratio [AOR] = 0.80
per year; p < 0.001). The overall probability of taking an
experimental antiretroviral (model 1) increased for those
who had experienced a higher number of antiretrovirals
(≥ 8d r u g sv e r s u s“naive": AOR = 3.71; p < 0.001) or
who had failed a higher number of antiretrovirals (3-4
drugs and ≥ 5 drugs versus 0-2 drugs: AOR = 1.42, p =
0.03, and 2.38, p < 0.001, respectively) and for those
who had an higher HIV viral load at regimen change (≥
4 log copies HIV RNA/ml versus < 2 log copies HIV
RNA/ml: AOR = 1.55, p = 0.02).
The probability of taking an experimental antiretro-
viral by participating in a clinical trial (model 2), was
significantly lower for patients presenting a liver comor-
bidity (AOR = 0.65; p = 0.05) and for those who experi-
enced 3-4 drugs compared to antiretroviral naive
patients (AOR = 0.55; p = 0.010), while it increased for
multi-treated patients (AOR = 2.60; p = 0.033). No sig-
nificant association was found for the number of failed
antiretrovirals and the viral load.
The probability of taking an experimental antiretro-
viral by participating in an EAP (model 3) was signifi-
cantly higher for patients infected through homosexual
contacts compared to those infected though heterosex-
ual contacts and for those who were married. The prob-
ability of taking an experimental antiretroviral trough an
EAP progressively increased with the increasing number
of drugs experienced, with the increasing number of
drugs failed and in those with a viral load at regimen
change ≥ 4 log copies/ml. Patients presenting a liver co
morbidity also had a higher probability of taking an
experimental antiretroviral through an EAP (AOR =
1.44; p = 0.053).
In all three models, age, gender, place of birth, educa-
tion, clinical stage (CD4 count or clinical AIDS), were
not significantly associated with the probability of
receiving an experimental antiretroviral. Similarly, no
association was found with the characteristics of a clini-
cal unit. On the other hand, the heterogeneity associated
with the clinical centre, not explained by the covariates
included in the model, was statistically significant in all
three models (table 3).
Discussion
Most of the published studies assessing access to experi-
mental antiretroviral drugs were based on cross-sec-
tional surveys on samples of persons with HIV
[9,10,12,14,22,23]. We addressed this issue by analyzing
data from a multi-centre cohort study over an 11-year
period.
We found that almost 10% of patients received an
experimental antiretroviral at least once. Marked varia-
tions were observed in different years of the study with
an overall tendency of decreasing probability of
Table 2 Use of experimental antiretroviral drugs in a therapy initiation/change episode by demographic/epidemiologi-
cal characteristics of patients and clinical and laboratory data at the time antiretroviral treatment (ART) initiation/
change (Continued)
200-349 45 (1.8) 49 (2.0) 2444
> = 350 83 (1.8) 95 (2.1) 4610
HIV RNA (log 10 copies/ml) < 0.001
< 2 22 (1.0) 31 (1.4) 2275
2-3 48 (2.0) 53 (2.3) 2345
> = 4 122 (2.5) 116 (2.4) 4812
Presence of hepatic comorbidities 0.01
No 127 (2.4) 103 (1.9) 5313
Yes 65 (1.6) 97 (2.3) 4128
Presence of other
b comorbidities 0.15
No 179 (2.1) 177 (2.1) 8384
Yes 13 (1.2) 23 (2.2) 1057
Number of experienced drugs < 0.001
Naive 117 (3.2) 42 (1.2) 3.647
3-4 44 (1.2) 74 (2.1) 3.524
5-7 15 (0.9) 50 (3.0) 1.675
> = 8 16 (2.7) 34 (5.7) 595
Number of failed drugs < 0.001
0-2 153 (2.3) 94 (1.4) 6.727
3-4 26 (1.3) 62 (3.3) 2.047
> = 5 13 (1.9) 44 (6.6) 667
a Expanded access program; b cardio-vascular/metabolic diseases or neoplasm
Girardi et al. BMC Health Services Research 2012, 12:38
http://www.biomedcentral.com/1472-6963/12/38
Page 7 of 12Table 3 Adjusted odds-ratios (AOR) of the use of experimental antiretroviral drugs in a therapy initiation/change
episode by demographic/epidemiological characteristics of patients and clinical and laboratory data at the time of
initiation/change
Model 1 Model 2 Model 3
Overall use of an
experimental
antiretroviral
Use of an experimental
antiretroviral in a clinical
trial
Use of an experimental
antiretroviral in an EAP
a
AOR 95%CI p AOR 95%CI p AOR 95%CI p
Total AIDS cases reported in the clinical centre 0.94 0.79 0.93
0-250 1.00 1.00 1.00
251-500 1.10 (0.64-1.91) 1.07 (0.50-2.29) 1.07 (0.58-1.96)
501-1000 1.03 (0.59-1.79) 0.97 (0.45-2.11) 0.99 (0.54-1.81)
> 1000 0.93 (0.54-1.60) 0.74 (0.35-1.59) 1.18 (0.65-2.11)
Type of clinical center 0.77 0.82 0.37
Non-teaching hospital 1.00 1.00 1.00
Teaching hospital 0.94 (0.62-1.42) 1.07 (0.61-1.88) 0.82 (0.53-1.27)
Gender 0.41 0.69 0.48
Female 1.00 1.00 1.00
Male 0.89 (0.67-1.18) 0.92 (0.62-1.37) 0.87 (0.59-1.28)
Age at therapy initiation/change (per 5 year increase) 1.00 (0.94-1.08) 0.90 0.99 (0.90-1.09) 0.82 1.02 (0.93-1.12) 0.70
Place of birth 0.36 0.97 0.14
Italy 1.00 1.00 1.00
Other countries 0.80 (0.51-1.28) 1.01 (0.56-1.83) 0.57 (0.28-1.19)
Years of education 0.64 0.76 0.81
< = 8 1.00 1.00 1.00
9-13 1.14 (0.87-1.48) 1.19 (0.82-1.73) 1.11 (0.77-1.59)
> 13 1.24 (0.75-2.05) 1.23 (0.60-2.50) 1.33 (0.67-2.64)
Unknown 0.96 (0.70-1.32) 0.97 (0.62-1.52) 0.97 (0.63-1.49)
Marital status 0.07 0.41 0.03
Never married 1.00 1.00 1.00
Married 1.25 (0.99-1.58) 1.15 (0.83-1.59) 1.43 (1.03-1.98)
Occupational status 0.79 0.92 0.81
Unemployed 1.00 1.00 1.00
Employed 1.08 (0.83-1.41) 1.08 (0.74-1.57) 1.07 (0.74-1.55)
Other 1.19 (0.65-2.17) 1.08 (0.46-2.53) 1.30 (0.57-2.97)
HIV exposure category 0.09 0.99 0.01
Heterosexual 1.00 1.00 1.00
Homosexual/Bisexual 1.33 (0.96-1.85) 1.05 (0.66-1.66) 1.67 (1.06-2.63)
IDU (Active+Former) 0.85 (0.60-1.19) 1.00 (0.61-1.64) 0.79 (0.50-1.24)
Other/Unknown 0.92 (0.57-1.47) 1.04 (0.57-1.88) 0.74 (0.35-1.55)
Clinical and laboratory data at treatment change
Clinical AIDS 0.81 0.12 0.24
No 1.00 1.00 1.00
Yes 0.96 (0.72-1.29) 0.71 (0.45-1.10) 1.25 (0.86-1.81)
CD4 cell count (cells/ml) 0.62 0.65 0.65
< 200 1.00 1.00 1.00
200-349 0.89 (0.66-1.21) 0.82 (0.54-1.25) 0.97 (0.64-1.48)
> = 350 1.02 (0.76-1.35) 0.89 (0.60-1.32) 1.15 (0.77-1.70)
HIV RNA (log 10 copies/ml) 0.05 0.99 0.01
< 2 1.00 1.00 1.00
2-3 1.27 (0.87-1.83) 1.05 (0.60-1.83) 1.39 (0.86-2.26)
> = 4 1.55 (1.07-2.23) 1.02 (0.58-1.80) 2.05 (1.28-3.28)
Presence of hepatic comorbidities 0.96 0.05 0.05
No 1.00 1.00 1.00
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Page 8 of 12receiving an experimental antiretroviral. Demographic
and epidemiological characteristics of patients were not
significant determinants of receiving experimental anti-
retrovirals. On the other hand, antiretroviral treatment
experience was associated with access to experimental
antiretrovirals both in trials and in EAP. Significant
variability was associated with clinical centres, although
no association was found with the specific characteris-
tics of the clinical units that were examined in this
analysis.
Previous studies have shown that persons with HIV
have an high access to clinical trials of antiretrovirals.
For example, surveys in the US found that 10-23% of
patients interviewed reported experimental antiretroviral
use [10,12,14,23]. These figures are generally higher
than what is reported in our study. However, these stu-
dies were conducted mostly during the 1990s when a
great number of new drugs were in registration studies
[24] and when the patients had limited treatment oppor-
tunities and large expanded access programs were set up
[25].
Our study also showed that 14.7% of patients who had
treatment initiation/change in 1997-1999 had access to
experimental antiretrovirals while this proportion
decreased thereafter. However, in 2004-2007 the propor-
tion of patients was still 3.3%, a figure which is higher
than that reported for cancer patients [26].
Treatment history was an important determinant of
accessing experimental antiretrovirals, however different
patterns were observed for clinical trials and EAPs. The
probability of receiving an experimental antiretroviral
through a clinical trial was greater for naïve patients
and when treatment was changed in patients who had
experienced a higher number of drugs. This probably
reflects the design of clinical trials that are mainly
focused on naïve and multi-experienced patients [27].
On the other hand, the probability of using an experi-
mental antiretroviral trough EAPs increased significantly
for the number of drugs experienced and for those
failed and for patients with. liver co-morbidities. Taken
together, our results suggest that possibility of accessing
experimental antiretrovirals has been and continues to
be an important opportunity for patients with limited
treatment options.
Previous studies suggested that access to experimental
antiretrovirals may be lower in female patients [10,12],
those with lower socio-economic status [17] and for eth-
nic minorities [12,14,17,23]. In our study, gender, occu-
pational status and years of education were not
associated with accessing experimental antiretrovirals.
Foreign born patients had a somewhat lower, although
not significantly, probability of receiving an experimental
antiretroviral compared to patients born in Italy. How-
ever, foreign born patients constituted only 7.6% of our
study population, so we may lack the power to detect
significant association between ethnic origin and access
to experimental drugs. In consideration of the increasing
proportion of foreign born patients among those diag-
nosed with HIV/AIDS in Italy [28] as well as in other
European countries [29] this aspect deserves close moni-
toring in the near future.
We observed a marked variability in access to experi-
mental antiretrovirals in patients cared for in different
clinical centres not captured by the covariates consid-
ered in our analysis. In a previous study, characteristics
of the clinical unit providing care to patients with HIV,
Table 3 Adjusted odds-ratios (AOR) of the use of experimental antiretroviral drugs in a therapy initiation/change epi-
sode by demographic/epidemiological characteristics of patients and clinical and laboratory data at the time of initia-
tion/change (Continued)
Yes 1.01 (0.76-1.33) 0.65 (0.43-0.99) 1.44 (1.00-2.09)
Presence of other
b comorbidities 0.85 0.98 0.96
No 1.00 1.00 1.00
Yes 1.04 (0.71-1.52) 0.99 (0.54-1.83) 1.01 (0.62-1.64)
Number of experienced drugs < 0.001 < 0.001 < 0.001
Naive 1.00 1.00 1.00
3-4 1.06 (0.78-1.44) 0.55 (0.35-0.87) 2.49 (1.58-3.93)
5-7 1.40 (0.91-2.15) 0.57 (0.28-1.15) 3.54 (1.99-6.30)
> 8 3.71 (2.13-6.45) 2.60 (1.08-6.28) 7.07 (3.43-14.56)
Number of failed drugs 0.002 0.94 < 0.001
0-2 1.00 1.00 1.00
3-4 1.42 (1.03-1.95) 1.07 (0.62-1.83) 1.57 (1.06-2.33)
> 5 2.38 (1.47-3.86) 1.17 (0.48-2.83) 2.96 (1.67-5.23)
Calendar year (1 year increase) 0.80 (0.76-0.84) < 0.001 0.78 (0.73-0.85) < 0.001 0.82 (0.76-0.88) < 0.001
Likelihood Ratio test for significance of Random effect < 0.001 < 0.001 0.001
a Expanded access program; b cardio-vascular/metabolic diseases or neoplasm
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funded HIV trial centre, were independently associated
with use of experimental drugs [17]. In our study no
association was found with the specific characteristics of
clinical unit examined, although, correlation between
the probability of entering a clinical trial or an EAP in
the same centres suggests the possible existence of com-
mon barriers to accessing experimental drugs. Previous
studies have identified time constraints, lack of staff and
training, concerns about new drugs as physicians as bar-
riers to enrolling in clinical trials [30,31]. It remains to
be determined whether such barriers had a role in
determining differences among the clinical centres parti-
cipating in this study.
It should be pointed out that our study was conducted
on patients with HIV who were enrolled in a cohort
study. Therefore, it can’tb er u l e do u tt h a tt h e yw e r e
more likely to be enrolled in clinical trials and EAPs
than patients under care who were not in clinical stu-
dies and thus we could have overestimated the probabil-
ity to access experimental antiretrovirals in Italy. On the
other hand, it should be noted that the study population
was recruited in a very large number of clinical centres
in diverse geographic locations and with different char-
acteristics, and that the distribution of our population
by age, gender and mode of HIV acquisition is similar
to that of AIDS cases reported in Italy during the study
period [28].
In the analysis, we assumed that an experimental anti-
retroviral was obtained through an EAP if it was started
after the first ethical approval in Italy of the program,
and participation in a clinical trial was not recorded in
the database. However, patients may have still be
enrolled in a clinical trial when the EAP was active, so
we may have misclassified some patients.
The study design also did not allow us to investigate
the possible role of a series of patient factors such as
fear of side-effects, distrust of researchers, concerns
about research, and interference in everyday life which
have been shown to represent significant barriers to
accessing antiretroviral drug trials [32].
Conclusions
In summary, our study shows that a substantial number
of persons with HIV had the opportunity to access
experimental antiretroviral drugs in our country and
suggests that gender and socio-economic factors did not
represent significant barriers to accessing these drugs.
This is consistent with speculation that a national health
system which provides universal access to care for per-
sons with HIV, such as the Italian health system, may
also reduce disparities in access to experimental drugs,
in particular when the experimental drug represent an
opportunity for patients with exhaustion of treatment
options.
On the other hand, we also found that the chance of a
patient of accessing experimental antiretroviral drugs
varied widely in different clinical units: this is a potential
source of non equity, and deserves further investigation.
This finding also suggest the need of developing a
national initiative aimed at facilitating the access of
patients from different clinical centres to research on
n e wd r u g s .I nt h i sc o n t e x t ,e s t a b l i s h i n gr e s e a r c hn e t -
works among clinical centres and increasing the patient
community information and involvement in clinical
research may be useful tools.
Appendix - The Icona Foundation Study
1. GOVERNING BODY
M. Moroni (Chair), G. Angarano, A. Antinori, G. Carosi,
R. Cauda, A. d’Arminio Monforte, G. Di Perri, M. Galli,
F .G h i n e l l i ,R .I a r d i n o ,G .I p p o l i t o ,A .L a z z a r i n ,F .M a z -
zotta, C.F. Perno, P.L. Viale, F Von Schlosser.
2. SCIENTIFIC SECRETARY
Ad ’Arminio Monforte
3. STEERING COMMITTEE
A. Ammassari, A. Antinori, C. Balotta, P. Bonfanti, M.R.
Capobianchi, A. Castagna, F. Ceccherini-Silberstein, A.
Cozzi-Lepri, A. d’Arminio Monforte, A. De Luca, C.
Gervasoni, E. Girardi, S. Lo Caputo, F Maggiolo, R.
Murri, C. Mussini, M. Puoti, C. Torti
4. STATISTICAL AND MONITORING TEAM
A Cozzi-Lepri, I Fanti, T Formenti
5. PARTICIPATING PHYSICIANS AND CENTERS
M .M o n t r o n i ,A .G i a c o m e t t i ,AC o s t a n t i n i ,A .R i v a
(Ancona); U. Tirelli, F. Martellotta (Aviano-PN); G.
A n g a r a n o ,N .L a d i s a ,( B a r i ) ;F .S u t e r ,F .M a g g i o l o( B e r -
gamo); PL: Viale, G. Verucchi, B Piergentili, (Bologna);
G. Carosi, G. Cristini, C. Torti, C. Minardi, D. Bertelli
(Brescia); T. Quirino, C Abeli (Busto Arsizio); P.E. Man-
coni, P. Piano (Cagliari); J Vecchiet, K Falasca (Chieti);
G Carnevale, S Lorenzotti (Cremona); F. Ghinelli, L.
Sighinolfi (Ferrara); F. Leoncini, F. Mazzotta, M. Pozzi,
S. Lo Caputo (Firenze); G. Pagano, G. Cassola, G Viscoli,
A. Alessandrini, R. Piscopo, G Mazzarello (Genova); F.
S o s c i a ,L .T a c c o n i( L a t i n a ) ;A .O r a n i ,R .R o s s o t t o
(Lecco); A. Chiodera, P. Castelli (Macerata); M Galli, A.
Lazzarin, G. Rizzardini, I Schlacht, A. d’Arminio Mon-
forte, AL Ridolfo, A Foschi, A Castagna, S Salpietro, S.
Merli, S. Melzi, M.C. Moioli, P Cicconi, T Formenti
(Milano); R. Esposito, C. Mussini (Modena); A Gori, F
Sabbatini (Monza), N. Abrescia, A. Chirianni, M. De
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Page 10 of 12Marco, R. Viglietti, (Napoli); C. Ferrari, P. Pizzaferri
(Parma); F Baldelli, B Belfiori (Perugia); G. Magnani, M.
A. Ursitti (Reggio Emilia); M. Arlotti, P. Ortolani
(Rimini); R. Cauda, M Andreoni, A. Antinori, G. Anto-
n u c c i ,P .N a r c i s o ,VT o z z i ,V .V u l l o ,A .D eL u c a ,M .
Zaccarelli, L Gallo, R. Acinapura, P. De Longis, M.P.
T r o t t a ,AM i c c o l i ,F .C a r l e t t i ,( R o m a ) ;M . S .M u r a ,G
Madeddu (Sassari); P. Caramello, G. Di Perri, G.C. Oro-
fino, M Sciandra (Torino); E. Raise, F. Ebo (Venezia); G.
Pellizzer, D. Buonfrate (Vicenza).
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